Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | PLK4 | O00444 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2462307 | 0.89 | MAPT (0.48) | KIF11CYP2C19MAPTL3MBTL1KMT2A | |
| SCHEMBL2390826 | 0.82 | KCNN4 (0.61) | KIF11NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL2392958 | 0.79 | KCNN4 (0.49) | KIF11PTGS2CYP2C9CYP2C19RAB9A | |
| SCHEMBL11136765 | 0.74 | POLB (0.49) | NPC1MIFCYP2C9CYP2C19RAB9A | |
| SCHEMBL6824816 | 0.74 | MAPT (0.47) | KIF11NPC1MIFCES2CES1 | |
| SCHEMBL15233482 | 0.73 | KIF11 (0.53) | KIF11 | |
| SCHEMBL8380156 | 0.73 | CYP1A2 (0.48) | CYP2C19MAPTL3MBTL1CNR1KMT2A | |
| SCHEMBL9879652 | 0.73 | MAPT (0.45) | KIF11CYP2C19MAPTL3MBTL1KMT2A | |
| SCHEMBL5056428 | 0.73 | MAPT (0.46) | KIF11NPC1MIFCES2CES1 | |
| SCHEMBL2391562 | 0.72 | KCNN4 (0.58) | KIF11MAPTALDH1A1KMT2AKCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017070536-A1 | METHODS AND AGENTS FOR TREATING DISEASES | ANGION BIOMEDICA CORP. (US) | 2017-04-27 | — | — | WO | disclosed |
| US-8026263-B2 | Methods for inhibiting neoproliferative changes in blood vessel walls | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026263-B2 | Methods for inhibiting neoproliferative changes in blood vessel walls | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026263-B2 | Methods for inhibiting neoproliferative changes in blood vessel walls | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-27 | — | — | US | disclosed |
| US-20090048270-A1 | Compounds, Methods And Devices for Inhibiting Neoproliferative Changes in Blood Vessel Walls | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-19 | — | — | US | disclosed |
| US-20070293554-A1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2007-12-20 | — | — | US | disclosed |
| US-7235577-B1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235577-B1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235577-B1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-26 | — | — | US | disclosed |
| US-6803375-B1 | IMMUNOMODULATION IN A MAMMALIAN PATIENT WITHOUT CAUSING SUBSTANTIAL INHIBITION OF CYTOCHROME P-450 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048270-A1 | Compounds, Methods And Devices for Inhibiting Neoproliferative Changes in Blood Vessel Walls | PGF, VEGFA, MKI67 | KIF11 2931/4885NPC1 1196/4885MIF 45/4885 |
| US-20070293554-A1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | NFATC1, ORAI1, KCNMA1 | KIF11 4687/4885NPC1 2816/4885MIF 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.